ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AZN Astrazeneca Plc

12,096.00
-14.00 (-0.12%)
20 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -14.00 -0.12% 12,096.00 12,086.00 12,092.00 12,118.00 12,038.00 12,090.00 1,525,268 16:35:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 31.47 187.42B
Astrazeneca Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AZN. The last closing price for Astrazeneca was 12,110p. Over the last year, Astrazeneca shares have traded in a share price range of 9,461.00p to 12,432.00p.

Astrazeneca currently has 1,550,189,338 shares in issue. The market capitalisation of Astrazeneca is £187.42 billion. Astrazeneca has a price to earnings ratio (PE ratio) of 31.47.

Astrazeneca Share Discussion Threads

Showing 3526 to 3549 of 6150 messages
Chat Pages: Latest  150  149  148  147  146  145  144  143  142  141  140  139  Older
DateSubjectAuthorDiscuss
20/12/2020
17:28
Oxford coronavirus vaccine approval expected shortly after Christmas,government sources claim

A vaccine a developed by the University of Oxford is set to be approved within days of Christmas, according to senior Whitehall sources.

The Medicines and Healthcare Regulatory Agency (MHRA) is believed to be set to authorise the vaccines on December 28 or 29 after final data is provided to the regulator on Monday...

www.independent.co.uk/news/uk/oxford-vaccine-approve-christmas-covid-b1776481.html

bountyhunter
20/12/2020
13:56
It won't get approval in US, I reckon, they will want more data. U.K. seems desperate they will pass.
montyhedge
19/12/2020
19:01
The Oxford/AstraZeneca coronavirus vaccine is still being reviewed, the UK’s medicine agency has said, amid reports that doses could be ready by 28 December.

It is thought that the Medicines and Healthcare products Regulatory Agency (MHRA) will give the vaccine the green light at some point during the week of 28 December, triggering its immediate rollout by the NHS.

But Whitehall sources said that while they hoped the vaccine would be available that week, it was by no means certain, and the authorisation could be delayed until the beginning of January.

The delay has caused frustration in Whitehall and the NHS, with the vaccine taking much longer to meet approval than the Pfizer vaccine, which was rolled out in the UK last week.

philanderer
19/12/2020
13:09
Vaccine to be approved 28th 29th December. It will make for a merry new year folks
bogman1
18/12/2020
22:26
And they have also bought the expertise to work on a new pipeline
bogman1
18/12/2020
20:39
I would assume AZN management remembered to check patent expiration dates before they launched the bid ??
smcni1968
18/12/2020
18:35
buywell notes others are belatedly talking about the generic problem




buywell314 Dec '20 - 18:35 - 3384 of 3429 Edit



These are already dire

Loads of negative values due to HUGE NET DEBT


buying Blockbuster expensive drugs for large monies is all to do with how long the IP lasts in terms of protection and exclusivity of markets

Once that goes the generics come along

buywell3
18/12/2020
12:40
From the RNS...Soliris's patent protection is waning, and the drug faces potential competition that could undercut sales. In June, Alexion reached a legal settlement with Amgen Inc. to delay its launch of a copycat drug until 2025.The delay gives Alexion crucial breathing room to persuade doctors to switch their patients onto a new drug called Ultomiris that is protected from U.S. competition until at least 2030.
gregb
18/12/2020
11:16
"ahead of generic competition"

That surprised me with the post. I would have thought that at that price there would be very long IP.

alphorn
18/12/2020
11:06
Liberum alert to AstraZeneca-Alexion bid risks

AstraZeneca’s (AZN) $37bn acquisition of US rare disease specialist Alexion (ALXN.O) works financially but Liberum says there are ‘some risks’.

Analyst Alistair Campbell retained his ‘buy’ recommendation on the stock but reduced his target price from £97.70 to £94.30. The shares fell 1.2% to £75.50 yesterday.

‘The deal works from a financial point of view, with low teens earnings per share accretion and a positive uplift to our discounted cashflow,’ he said.

‘However, there are some risks. Alexion needs to switch its lead drug into its second generation product ahead of generic competition, and there’s some risk of a counterbid forcing the deal value upwards.’

However, Campbell said he had reset his forecasts on the assumption the deal would complete.

philanderer
18/12/2020
08:59
Three director buys in the last few days.

Not insignificant amounts either - two of them each bought £100,000 worth.

bluemango
18/12/2020
00:22
2021 will see ‘vaccine cooperation, not competition,’ Russian official says after AstraZeneca tie-up
philanderer
17/12/2020
11:44
I go with the 6700p.
montyhedge
17/12/2020
11:27
Single targeted mRNA Vaccines for single Covi-19 strain.

Now there are 4 strains.

ftse100djia
17/12/2020
11:23
Take your pick ;-)

17th dec Liberum buy tp 9430p
17th dec DZ Bank sell tp 6700p

philanderer
17/12/2020
00:47
U.K. Hopes Oxford-Astra Vaccine Will Be Ready by Early New Year
philanderer
16/12/2020
13:59
Rebounding nicely
smcni1968
16/12/2020
08:26
Prefer GSK 5.9% yield over Astra's at the moment.
montyhedge
15/12/2020
23:45
You're the Professor ...
smcni1968
15/12/2020
21:28
How can i buy this share
professor_peaky
15/12/2020
19:31
Astra and GSK both down 2.4% today
smcni1968
15/12/2020
19:06
AZN threw quite a lot of news at the markets over the last couple of days imo to try to keep the share price at levels that helped the bid for Alexion

buywell wonders how much more positive newsflow azn has left in the locker that can now counteract market sentiment

buywell is still of the opinion that investors in the USA will have to come to terms with reality of the Global Downturn taking place and Covid-19 continuance

Stimulus packages forever otherwise in a Covid-19 endemic

Other actions needed see BUY

Mass Testing has caused Politicians to NOT carry out National Lockdowns as it has fudged the issue with false hopes as has masks and track and trace

Lack of National Lockdowns of at least 8 weeks duration or better still 12 weeks

Has caused the worldwide mess we are now in ---- and getting worse buy the day

Germany is locking down till Jan 10th ie not enough like Holland and the Czech Republic

Italy will act later this week or else go into meltdown

buywell3
15/12/2020
19:05
buywell, remind me what that was ? thanks
philanderer
15/12/2020
18:55
Not true --- you bought a stock buywell recommended on NFDS but have recently sold
Well done buy the way u must have done well

philanderer
14 Dec '20 - 20:11 - 3389 of 3412
0 1 0
matt, I'm not expecting one, I've tried a couple of times before and got blanked ;-)

buywell3
Chat Pages: Latest  150  149  148  147  146  145  144  143  142  141  140  139  Older

Your Recent History

Delayed Upgrade Clock